On August 15, 2014, Biogen Idec announced that the United States Food and Drug Administration (FDA) had approved Plegridy™ (peginterferon beta-1a) for the long-term treatment of relapsing forms of multiple sclerosis (MS). Manufactured by Biogen Idec, this new medication is the 11th disease-modifying therapy (DMT) to be approved for MS since the early 1990s. Plegridy is given once every two weeks through a subcutaneous self-injection.
Read News ArticleAuthor: Hoff Communications
Program Notes: Know Your Insurance Options
MSAA proudly announces the creation of a new addition to the mymsaa.org website, dedicated exclusively to helping the MS community better understand and utilize health insurance. Titled, My Health Insurance Guide, this comprehensive online resource center offers a wealth of easy-to-follow information about the Health Insurance Marketplace under the Affordable Care Act (ACA), Medicare, Medicare Advantage, and Medicaid.
Read News ArticleThoughts about Giving: Let Us Help You Help Others
In previous articles in The Motivator and posts on our blog, MS Conversations, I have talked about the current controversy over whether charity ratings are really helpful in giving a true picture of an organization’s effectiveness in meeting their mission. Does a number or a star really help you know if a nonprofit is having an impact?
Read News ArticleStories to Inspire: A Psychologist’s Perspective of His Own MS
People in any career field may develop multiple sclerosis – it does not discriminate – and this includes doctors too. Mack Stephenson, PhD is a psychologist who began exhibiting the symptoms of MS while in the service, although he was not diagnosed until after leaving the Navy. As both a doctor and a teacher, he decided to learn about the disease and its treatments, and then write about his experiences and observations. To follow are some key passages from Dr. Stephenson’s book. We’re also proud to feature someone who served our country.
Read News ArticleSpread the Word
Two books from MSAA’s free Lending Library are featured.
Read News ArticleHighlights from the 2014 Joint ACTRIMS-ECTRIMS Meeting
Every three years, two international organizations come together to share, discuss, and debate the most recent basic and clinical research findings in the area of multiple sclerosis (MS). The joint meeting, alternately hosted in North America and Europe, took place in Boston, Massachusetts September 10th through 13th.
Read News ArticleThe Multiple Sclerosis Association of America Launches Health Insurance Guide for Individuals with MS
The Multiple Sclerosis Association of America (MSAA), a national nonprofit organization and leading resource for individuals with multiple sclerosis (MS), announces the launch of a new website addition accessed at mymsaa.org. Titled My Health Insurance Guide, this dedicated section provides comprehensive, easy-to-follow information and resources for the MS community about the Health Insurance Marketplace under the Affordable Care Act (ACA), Medicare, Medicare Advantage, and Medicaid.
Read News ArticleAAN Seeks Public Feedback on MS Quality Measures
The American Academy of Neurology (AAN) has formed a multidisciplinary team, including physicians, nurses, rehabilitation specialists, cognitive researchers, mental-health professionals, and patient advocates to improve overall patient outcomes. The group of experts reviewed current guidelines and evidence, gaps in care, and developed a “measurement set” for multiple sclerosis.
Read News ArticleMSC Publishes Professional Consensus Paper on DMTs
Experts from member organizations of the Multiple Sclerosis Coalition (MSC), including the Multiple Sclerosis Association of America (MSAA), collaborated to develop and write a paper summarizing the current evidence that supports the FDA-approved disease-modifying therapies (DMTs) for the long-term treatment of multiple sclerosis (MS).
Read News ArticlePlegridy™ Approved for Relapsing Forms of MS
On August 15, 2014, Biogen Idec announced that the United States Food and Drug Administration (FDA) had approved Plegridy™ (peginterferon beta-1a) for the long-term treatment of relapsing forms of multiple sclerosis (MS). Manufactured by Biogen Idec, this new medication is the 11th disease-modifying therapy (DMT) to be approved for MS since the early 1990s. Plegridy is given once every two weeks through a subcutaneous self-injection.
Read News Article